TD Asset Management Inc. Has $2.33 Million Holdings in Jazz Pharmaceuticals PLC (JAZZ)

TD Asset Management Inc. lowered its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 12.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,945 shares of the specialty pharmaceutical company’s stock after selling 2,288 shares during the period. TD Asset Management Inc.’s holdings in Jazz Pharmaceuticals were worth $2,332,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of JAZZ. Janus Henderson Group PLC lifted its holdings in Jazz Pharmaceuticals by 11,990.7% during the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock worth $135,894,000 after buying an additional 866,691 shares during the period. FMR LLC lifted its holdings in Jazz Pharmaceuticals by 11.4% during the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after buying an additional 849,348 shares during the period. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after buying an additional 410,031 shares during the period. American Century Companies Inc. lifted its holdings in Jazz Pharmaceuticals by 133.2% during the second quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock worth $85,509,000 after buying an additional 314,094 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Jazz Pharmaceuticals by 1,296.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 187,237 shares of the specialty pharmaceutical company’s stock worth $29,115,000 after buying an additional 173,825 shares during the period. Institutional investors own 91.30% of the company’s stock.

JAZZ has been the subject of a number of analyst reports. Cowen set a $190.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. HC Wainwright initiated coverage on Jazz Pharmaceuticals in a report on Friday, August 25th. They set a “neutral” rating and a $144.00 target price for the company. Wells Fargo & Company restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, August 30th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $181.28.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at $138.97 on Friday. The company has a market capitalization of $8,083.13, a price-to-earnings ratio of 16.92, a PEG ratio of 0.87 and a beta of 0.98. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals PLC has a twelve month low of $101.37 and a twelve month high of $163.75.

In related news, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now owns 1,365 shares in the company, valued at approximately $181,804.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Iain Mcgill sold 8,000 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the completion of the transaction, the senior vice president now owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The disclosure for this sale can be found here. Insiders sold a total of 10,352 shares of company stock valued at $1,417,763 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/12/10/td-asset-management-inc-has-2-33-million-holdings-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply